How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,868 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. HIV and STI testing among Indigenous women and women who inject drugs

provided HIV testing and pre- and post-test counselling. Women’s- only needle exchange services were also provided at workshops whenever possible. Participants received grocery store gift cards for being tested, for returning for STI and HIV test results, and for attending each of the four educational workshops (10). Over the course of three years, the WORKS intervention engaged 562 participants – 68% of whom were current or former injection drug users. HIV and STI testing rates were high (...) HIV and STI testing among Indigenous women and women who inject drugs RAPID RESPONSE SERVICE | #105, MAY 2016 1 Questions What programs and services have been shown to be effective in increasing HIV and STI testing among Indigenous women and women who inject drugs? References 1. Orchard TR, Druyts E, McInnes CW , Clement K, Ding E, Fernandes KA et al. Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. AIDS Care 2010 March;22(3):324-31. 2. Lally MA

2016 Ontario HIV Treatment Network

82. Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations

Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations TECHNICAL REPORT Antenatal screening approaches effective in preventing mother- child-transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations Literature review www.ecdc.europa.euECDC TECHNICAL REPORT Antenatal screening approaches effective in preventing mother-to-child transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations (...) Leino, Markku Kuusi, and Mika Salminen Helena de Carvalho Gomes and Ana-Belen Escriva are acknowledged for internal ECDC support. Suggested citation: European Centre for Disease Prevention and Control. Antenatal screening approaches effective in preventing mother-child-transmission of HIV, hepatitis B, syphilis and rubella in vulnerable populations. Stockholm: ECDC; 2017. Stockholm, March 2017 ISBN 978-92-9498-032-8 doi: 10.2900/580446 Catalogue number TQ-02-17-142-EN-N © European Centre for Disease

2017 European Centre for Disease Prevention and Control - Literature Reviews

83. Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe

) may promote risk taking and undermine established social norms. However, over the course of the HIV epidemic, evidence points in a different direction. Many new and successful prevention strategies were developed in the MSM community; condom use among MSM increased as soon as AIDS was linked to sex, and AIDS activists promoted the practice through their networks. The concept of ‘negotiated safety’ also originated in the MSM community, long before the concept was given a name, defined and promoted (...) Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe www.ecdc.europa.eu Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe TECHNICAL DOCUMENT ECDC TECHNICAL DOCUMENT Communication strategies for the prevention of HIV, STIs and hepatitis among MSM in Europe ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Irina Dinca, Piotr Wysocki, Anastasia Pharris

2016 European Centre for Disease Prevention and Control - Technical Guidance

84. Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients (PubMed)

Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients Introduction. Pneumocystis pneumonia (PCP) is rising in the non-HIV population and associates with higher morbidity and mortality. The aggressive immunosuppressive regimens, as well as the lack of stablished guidelines for chemoprophylaxis, are likely contributors to this increased incidence. Herein, we have explored the underlying conditions, immunosuppressive therapies, and clinical (...) outcomes of PCP in HIV-negative patients. Methods. Retrospective analysis of PCP in HIV-negative patients at Mayo Clinic from 2006-2010. The underlying condition, immunosuppressive therapies, coinfection, and clinical course were determined. PCP diagnosis required symptoms of pneumonia and identification of the organisms by visualization or by a real-time polymerase chain reaction. Results. A total of 128 cases of PCP were identified during the study period. Hematological malignancies were

Full Text available with Trip Pro

2016 Canadian respiratory journal

85. HIV and adolescents: Guidance for HIV testing and counselling and care for adolescents living with HIV

HIV and adolescents: Guidance for HIV testing and counselling and care for adolescents living with HIV RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH AND CONSIDERATIONS FOR POLICY-MAKERS AND MANAGERS HIV AND ADOLESCENTS: GUIDANCE FOR HIV TESTING AND COUNSELLING AND CARE FOR ADOLESCENTS LIVING WITH HIV United Nations Educational, Scienti?c and Cultural Organization ISBN 978 92 4 150616 8 HIV AND ADOLESCENTS: GUIDANCE FOR HIV TESTING AND COUNSELLING AND CARE FOR ADOLESCENTS LIVING WITH HIV ? World (...) Health Organization 20, avenue Appia CH–1211 Geneva 27 Switzerland For more information, contact: ? Department of HIV/AIDS E-mail: hiv-aids@who.int http://www.who.int/hiv/en/ ? Department of Maternal, Newborn, Child and Adolescent Health Email: mncah@who.int http://www.who.int/maternal_child_adolescent/en/RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH AND CONSIDERATIONS FOR POLICY-MAKERS AND MANAGERS HIV AND ADOLESCENTS: GUIDANCE FOR HIV TESTING AND COUNSELLING AND CARE FOR ADOLESCENTS LIVING

2013 World Health Organisation HIV Guidelines

86. Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics???

Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? | BMJ EBM Spotlight by A recent BMJ analysis article argued that taking the “full course of antibiotics” is often likely counterproductive (see doi: 10.1136/bmj.j3418 )​. Details: –international health organizations and the WHO have pushed for completing antibiotic regimens: a 2016 WHO advisory to patients stated “always complete (...) the full prescription, even if you feel better, because stopping treatment early promotes the growth of drug-resistant bacteria”. The CDC has a similar message –the authors note that there is impressive evidence that some micro-organisms (eg TB, gonorrhea, HIV, S. typhi) can create spontaneous resistant mutations on treatment, and these mutants subsequently can be transmitted as resistant strains. [and there are good data supporting longer term therapies] –but many of the organisms with growing

2017 Evidence-Based Medicine blog

87. Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics???

Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? | BMJ EBM Spotlight by A recent BMJ analysis article argued that taking the “full course of antibiotics” is often likely counterproductive (see doi: 10.1136/bmj.j3418 )​. Details: –international health organizations and the WHO have pushed for completing antibiotic regimens: a 2016 WHO advisory to patients stated “always complete (...) the full prescription, even if you feel better, because stopping treatment early promotes the growth of drug-resistant bacteria”. The CDC has a similar message –the authors note that there is impressive evidence that some micro-organisms (eg TB, gonorrhea, HIV, S. typhi) can create spontaneous resistant mutations on treatment, and these mutants subsequently can be transmitted as resistant strains. [and there are good data supporting longer term therapies] –but many of the organisms with growing

2017 Evidence-Based Medicine blog

88. HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

, the DSMB recommended that all study participants should be offered study drug. A total of 23 participants became infected with HIV over the course of the study: three in the daily TDF-FTC group and 20 in the deferred (no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3–11.3) The relative risk reduction was 86% (90% CI 64–96%) and the number needed to treat over 1 year to prevent one HIV infection was 13 (90% CI 9–23). BHIVA/BASHH guidelines on the use (...) followed up every 8 weeks for HIV testing and risk-reduction advice, and every 6 months for sexually transmitted infection (STI) testing for a total of 431 person-years of follow-up. Primary endpoint was HIV infection. At interim review, the placebo group was discontinued and all study participants were offered study drug. Over the course of the study, 16 people became infected with HIV: two in the TDF-FTC group and 14 in the placebo group, representing a relative risk reduction of 86% (95% CI 40–98

2018 British HIV Association

89. Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection (PubMed)

and disseminated KS is presented in two patients with HIV/AIDS. CASE REPORT A 25-year-old man and a 30-year-old man with HIV/AIDS presented with KS affecting the skin, oral cavity, gastrointestinal tract, liver, lungs, kidneys, adrenal glands, and bone. Both patients had a rapidly deteriorating clinical course associated with a low CD4 count and developed respiratory failure and death. CONCLUSIONS Fatal disseminated KS is associated with severe immunosuppression due to with a low CD4 count. The presentation (...) of these two cases highlights the potentially aggressive clinical course of KS in patients with HIV/AIDS and reinforces the need for early diagnosis and rapid treatment with HAART.

Full Text available with Trip Pro

2018 The American journal of case reports

90. Association of Increased Chronicity of Depression With HIV Appointment Attendance, Treatment Failure, and Mortality Among HIV-Infected Adults in the United States. (PubMed)

of failure at multiple points along the HIV care continuum. Even modest increases in the proportion of time spent with depression led to clinically meaningful increases in negative outcomes. Clinic-level trials of protocols to promptly identify and appropriately treat depression among adults living with HIV should be conducted to understand the effect of such protocols on shortening the course and preventing the recurrence of depressive illness and improving clinical outcomes. (...) Association of Increased Chronicity of Depression With HIV Appointment Attendance, Treatment Failure, and Mortality Among HIV-Infected Adults in the United States. Depression commonly affects adults with HIV and complicates the management of HIV. Depression among individuals with HIV tends to be chronic and cyclical, but the association of this chronicity with HIV outcomes (and the related potential for screening and intervention to shorten depressive episodes) has received little attention.To

2018 JAMA psychiatry (Chicago, Ill.)

91. HIV-1-Gag Conserved-Element DNA Vaccine as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy

HIV-1-Gag Conserved-Element DNA Vaccine as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy HIV-1-Gag Conserved-Element DNA Vaccine as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HIV-1-Gag Conserved-Element DNA Vaccine as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care

2018 Clinical Trials

92. Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x (...) × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2018 Clinical Trials

93. A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults - Full (...) Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein

2018 Clinical Trials

94. Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults The safety and scientific validity of this study is the responsibility

2018 Clinical Trials

95. HIV DNA: a clinical marker of HIV reservoirs. (PubMed)

HIV DNA: a clinical marker of HIV reservoirs. A number studies are currently underway to develop new drugs aimed at reducing the HIV reservoir or achieving ART-free control of HIV infection. Many markers of HIV reservoirs have been proposed, each one having a different meaning. Total HIV DNA dynamics during the course of HIV infection and its predictive value are now well known. This marker allowed to estimate the size of HIV reservoir at different stages of HIV infection in blood, cell subsets (...) and tissues. Therefore, the purpose of this review is timely and relevant, with the objective to discuss how total HIV DNA might be helpful in the clinical settings.Among the markers, it appears that HIV DNA is the most well studied, and recent articles confirmed that this marker is easy to use and is precise, specific, practical, robust and reproducible. All these characteristics correspond to what is expected from a helpful clinical marker.HIV DNA level could be considered as a global marker

2018 Current opinion in HIV and AIDS

96. A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Phase 1/2a Study of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

97. 90-90-90 HIV targets: implications for HIV-associated tuberculosis. (PubMed)

a comprehensive HIV and TB care continua.In 2016, people living with HIV (PLHIV) on antiretroviral treatment (ART) ranged from 13 to 84%; viral suppression ranged from 21 to 79%. Only 5% of PLHIV without TB reported a course of isoniazid preventive therapy (IPT). TB treatment success (2015) ranged from 34 to 94%. Data for the combined indicators: TB treatment success and viral suppression and IPT and ART for PLHIV are not collected. Reported 2003-2017 global international and domestic resources for TB and HIV (...) 90-90-90 HIV targets: implications for HIV-associated tuberculosis. The HIV and Mycobacterium tuberculosis syndemic remains a major global public health threat. HIV and tuberculosis (TB) global targets have been set. Success will depend on achieving combined disease control. We explore current policy, economic investment, and disease control strategies for HIV, TB, and HIV-associated TB. We review published HIV, TB, and HIV-associated TB data for 30 WHO priority countries and propose

2018 Current opinion in HIV and AIDS

98. Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1 infected individuals. (PubMed)

the course of the study and no difference between cell-associated HIV-1 RNA and DNA diversity (P = 0.32). Only one participant showed signs of potential vaccine-related selection in the rebounding plasma virus. In five of seven participants, we identified human leukocyte antigen-specific cytotoxic T lymphocytes (CTL) epitopes containing nonsilent mutations in 100% of the sequences.We detected no evidence of selective immune pressure reflected in proviral diversity or by occurrence of specific mutation (...) Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1 infected individuals. Therapeutic HIV-1 immunization followed by latency reversal has been suggested as a strategy to eradicate HIV-1. Here we investigate the phylogenetic composition of the HIV-1 regions targeted by the therapeutic HIV-1 peptide vaccine Vacc-4x in participants in a clinical trial.Seventeen participants on suppressive antiretroviral therapy were vaccinated with six doses of Vacc-4x

Full Text available with Trip Pro

2018 AIDS

99. Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France

Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France (PARCOURS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02566148 Recruitment Status : Completed First Posted : October 2, 2015 Last Update Posted : May 15, 2017 Sponsor: French National Institute for Health

2015 Clinical Trials

100. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>